Antibacterial *Curcuma xanthorrhiza* Extract and Fractions

Hartiwi Diastuti[1,3], Yana M. Syah[1]*, Lia D. Juliawaty[1], Marlia Singgih[2]

[1]Organic Chemistry Division, Institut Teknologi Bandung,
Jalan Ganesha 10, Bandung 40132, Indonesia
[2]School of Pharmacy, Institut Teknologi Bandung,
Jalan Ganesha 10, Bandung, Indonesia
[3]Chemistry Program, Universitas Jenderal Soedirman,
Jl. HR Boenyamin 708 Purwokerto 53122. Indonesia
*Email: yana@chem.itb.ac.id

Abstract. An acetone extract of *Curcuma xanthorrhiza* rhizomes and the *n*-hexane and chloroform fractions obtained from it were tested on eight pathogenic bacteria. The results showed that the acetone extract and the *n*-hexane fraction exhibited significant activities against *Bacillus subtilis*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*, and weak activities against *Shigella dysenteriae* and *Vibrio cholerae*. They were inactive against *Escherichia coli*, *Enterobacter aerogenes* and *Salmonella thypi*, while the chloroform fraction was devoid of activities. NMR analysis disclosed the presence of α-curcumene, xanthorrhizol and an unknown monoterpene in the *n*-hexane fraction. In the chloroform fraction, curcumin was found to be the main compound, together with xanthorrhizol as a minor compound. These results suggest that the antibacterial potency of acetone extract of *C. xanthorrhiza* is contained in the *n*-hexane fraction, in which the active constituents are terpenoid compounds. This is the first report of the use of NMR analysis for compound identification contained in an extract or fractions of *C. xanthorrhiza*.

1   Introduction

Although the main sources of antibiotics are bacteria and fungi, recently there has been interest to look for new bioactive compounds from plants that are capable to partly or completely suppress microbial infections [1]. This approach represents an attractive strategy to control the spread of microbial drug resistance and it could maintain the use of existing antibiotics that are often cheaper and less toxic than new candidate antimicrobials [2]. *Curcuma xanthorrhiza* Roxb. is one of the herbs that are popular in Indonesian *jamus* [3]. The rhizomes of this plant have been known to contain terpenoid and curcuminoid compounds [4-10]. Beneficial properties of curcuminoids, such as antioxidant, anti-imflammatory, antitumor, and anticancer effects, have been investigated by many researchers for a long time [11-13]. Recently, interest in

terpenoid extract and its major constituent, xanthorrhizol, as antibacterial and antifungal agents has attracted some reseachers [14-18]. These studies were motivated by the fact that synthetic antibiotics, apart from their broad and strong antimicrobial properties, are believed to have long-term side effects. In addition, pathogenic microorganisms are constantly developing resistance to these drugs [19]. As an initial study toward finding new antibacterial compounds from Indonesian plants, the present study reports antibacterial properties of an acetone extract and fractions obtained from the rhizomes of *C. xanthorrhiza* against eight bacteria, as well as the analysis of their constituents using the NMR method. This the first report of the use of NMR analysis, particularly using TOCSY1D (Total Correlation Spectroscopy One Dimensional) experiments, for identification of the compounds contained in an extract or fractions obtained from rhizomes of *C. xanthorrhiza*.

Table 1 MIC and MBC values of Cx-TA (acetone extract), Cx-H (*n*-hexane fraction) and Cx-C (chloroform fraction) against eight pathogenic bacteria.

		Cx-TA	Cx-H	Cx-C	Amox	Chloram
Bacillus subtilis	MIC	31.2	62.5	>1000	31.2	3.9
(gram +)	MBC	62.5	62.5	>1000	62.5	3.9
Staphylococcus aureus	MIC	62.5	62.5	>1000	3.9	3.9
(gram +)	MBC	62.5	62.5	>1000	3.9	7.8
Escherichia coli	MIC	>1000	>1000	1000	31.2	3.9
(gram −)	MBC	>1000	>1000	1000	62.5	3.9
Enterobacter aerogenes	MIC	>1000	500	1000	125	15.6
(gram −)	MBC	>1000	500	1000	125	31.2
Pseudomonas aeruginosa	MIC	7.8	7.8	>1000	62.5	31.2
(gram −)	MBC	15.6	15.6	>1000	62.5	31.2
Shigella dysentriae	MIC	250	250	>1000	15.6	3.9
(gram −)	MBC	250	250	>1000	15.6	7.8
Salmonella thypi	MIC	>1000	>1000	>1000	3.9	3.9
(gram −)	MBC	>1000	>1000	>1000	3.9	7.8
Vibrio cholereae	MIC	500	250	500	62.5	31.2
(gram −)	MBC	500	500	500	125	31.2

MIC and MBC values are in μg/mL; Amox = amoxicillin; Cloram = chloramphenicol.

2   Results and Discussion

Extraction of dried powder of *C. xanthorrhiza* with acetone resulted a dark yellow of gummy material. Liquid-liquid fractionation of the acetone extract into *n*-hexane, $CHCl_3$, and EtOAc gave a viscous liquid of *n*-hexane, $CHCl_3$, and EtOAc fractions. The combined weight of the first two fractions showed that practically most of the mass of the extract was soluble in these fractions. Antibacterial activities of the total acetone extract (Cx-TA), *n*-hexane (Cx-H), and $CHCl_3$ (Cx-C) fractions are presented in Table 1 as MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) values. As shown in the table, except for *S. aureus* and *S. thypi*, all the tested bacteria were resistant to amoxicillin, while *E. aerogenes*, *P. aeruginosa*, and *V. cholerae* were not susceptible to chloramphenicol. Treatment with Cx-TA and Cx-H showed that they strongly inhibited the growth of *P. aeruginosa* at a concentration much lower than amoxicillin and chloramphenicol (MICs 7.8, 7.8, 62.5, and 31.2 µg/mL, respectively). The Cx-TA and Cx-H also exhibited potent bactericidal effects on this microorganism (both have an MBC value of 15.6 µg/mL). From the MIC and MBC values, Cx-TA and Cx-H showed moderate antibacterial properties against *B. subtilis* and *S. aureus* and were inactive against the remaining tested bacteria. Meanwhile, the Cx-C fraction showed no activity against all tested bacteria.

The ^{1}H NMR data of Cx-TA, Cx-H, and Cx-C are presented in Figure 1. Analysis of these spectra showed that α-curcumene (**1**) and xanthorrhizol (**2**) were the major constituents in the Cx-H, with a mole ratio of almost 1:1, while no curcumin was detected. The aromatic proton signals of compounds **1** and **2** were easily identified from their multiplicities, while identification of the aliphatic proton signals was aided by the TOCSY-1D spectra, as shown in Figure 2. Through a detailed analysis of the HSQC and HMBC spectra of Cx-H (data not shown), the ^{1}H and ^{13}C NMR parameters of compounds **1** and **2** could be determined (Table 2), thus confirming the identity of these compounds as xanthorrizol (**2**) and α-curcumene (**1**), respectively. In addition to these compounds, the Cx-H also contained an unknown terpenoid compound, possibly a monoterpene. Different to the Cx-H fraction, the Cx-C fraction contained curcumin (**3**) as its main constituent (NMR parameters data not shown). In this fraction, xanthorrhizol (**2**) was also found, with a **3**:**2** mole ratio of about 2.3:1. This is the first study to analyze the extract and fractions using extensive 1-D and 2-D NMR methods, including TOCSY1D experiments. The presence of compound **2** in the Cx-H is interesting because an essential oil obtained from the rhizomes of this plant collected from India showed an absence of this compound [14], while a similar oil from Indonesia contained compound **2** as the major constituent [20].

Figure 1 ^{1}H NMR spectra of the acetone extract (Cx-TA) (A); *n*-hexane (Cx-H) (B) and chloroform (Cx-C) (C) fractions of *C. xanthorrhiza* in CDCl$_3$. a, b, and c are signals due to α-curcumene (**1**), xanthorrhizol (**2**), and curcumin (**3**), respectively.

Biological properties of the extracts and essential oils from *C. xanthorrhiza* have been studied by many researchers. They include hepatoprotective and antinocetiptive activities [21,22], antihypercholesterolemic and cancer chemoproptective effects [23,24], and antimicrobial properties [14,25,26]. However, in this study the antibacterial activities of an extract and fractions of *C. xanthorrhiza* against eight pathogenic bacteria were investigated for the first time. The results revealed that only the total acetone extract (Cx-TA) and the *n*-hexane fraction (Cx-H) showed significant antibacterial activities against *P. aeruginosa* and moderate activities against *B. subtilis* and *S. aureus*. Weak or no activity was observed when tested to *S. dysentriae*, *V. cholerae*, *E. coli*, *E. aerogenes*, and *S. thypi*. On the other hand, the chloroform fraction (Cx-C) did not exhibit any activity against the tested bacteria, suggesting that the active constituent(s) of the extract is mainly contained in the Cx-H. From NMR analysis of the Cx-H, the active constituent(s) could be either α-curcumene (**1**), xanthorrhizol (**2**), or an unidentified terpenoid compound, or a combination of these compounds.

Figure 2 The ^{1}H TOCSY-1D spectra of the *n*-hexane fraction showing proton signals for α-curcumene (**1**), xanthorrhizol (**2**), and an unidentified monoterpene.

To our knowledge the only biological property reported for compound **1** was antitumor activity against Sarcoma 180 Ascities in mice [27]. Its antitumor activity was higher than that of compound **2**. However, compound **2** has been studied for a number of biological targets, notably for its antimicrobial [14-18] and anticancer [28-36] properties. In conclusion, this study has shown that the antibacterial capacity of *C. xanthorrhiza* is contained in the *n*-hexane fraction. By using an extensive 1-D and 2-D NMR analysis, the major components of this fraction could be identified.

3 Experimental Procedure

3.1 Plant Material

Rhizomes of *C. xanthorrhiza* were collected from Surakarta, Central Java, Indonesia, on March 2010, and were identified by staff of Herbarium Bandungense, School of Biological Sciences and Technology, Institut Teknologi Bandung.

3.2   Extraction and Fractionation

Dried powder of *C. xanthorrhiza* (100 g) was macerated with acetone (3 x 24 hours) to give a dark yellow acetone extract (7.3 g) after evaporating the solvent under reduced pressure. The acetone extract (Cx-TA) was partitioned into MeOH-*n*-hexane (1:1) to give *n*-hexane and MeOH fractions. The MeOH fraction was further partitioned into water-CHCl$_3$ to give CHCl$_3$ and aqueous-MeOH fractions. The aqueous-MeOH layer was extracted into an EtOAc fraction. The *n*-hexane, CHCl$_3$, and EtOAc fractions were evaporated under reduced pressure to get Cx-H (5.5 g), Cx-C (1.2 g), and Cx-E (105 mg) fractions, respectively.

Table 2 ^{1}H (500 MHz) and ^{13}C (125 MHz) NMR data of α-curcumene (**1**) and xanthorrhizol (**2**) in CDCl$_3$

No C	α-Curcumen (1)		Xanthorrhizol (2)	
	δ_H (*mult.*, *J* in Hz)	δ_C	δ_H (*mult.*, *J* in Hz)	δ_C
1	7.08 (*d*, 8.3)	126.8	6.23 (*d*, 1.5)	113.5
2	7.11 (*d*, 8.3)	128.9	-	153.8
3	-	135.0	-	121.0
4	7.11 (*d*, 8.3)	128.9	7.03 (*d*, 7.6)	130.6
5	7.08 (*d*, 8.3)	126.8	6.67 (*dd*, 7.6, 1.5)	119.1
6	-	144.6	-	147.0
7	2.67 (*sext.*, 7.0)	39.0	2.61 (*sext.*, 7.0)	39.0
8	1.68-1.54 (*m*)	38.4	1.66-1.50 (*m*)	38.3
9	1.85-1.95 (*m*)	26.0	1.85-1.95 (*m*)	26.1
10	5.11 (*tm*, 7.0)	124.8	5.10 (*tm*, 7.0)	124.5
11	-	131.0	-	131.3
12	1.69 (br*s*)	25.7	1.69 (br*s*)	25.6
13	1.60 (br*s*)	17.6	1.55 (br*s*)	17.6
14	1.23 (*d*, 7.0)	22.4	1.20 (*d*, 7.0)	22.3
15	2.33 (*s*)	20.9	2.24 (*s*)	15.4

3.3   NMR Analysis

^{1}H, ^{13}C, TOCSY-1D, HSQC-DEPT, and HMBC measurements of the acetone extract, *n*-hexane-, and CHCl$_3$-fractions were carried out in CDCl$_3$ with an Agilent DD2 spectrometer operating at 500 (^{1}H) and 125 (^{13}C) MHz, using the standard pulses of the spectrometer.

4 Antibacterial Evaluation [37]

The eight strains of bacteria used in this study include two gram-positive bacteria (*Bacillus subtilis* and *Staphylococcus aureus*) and six gram-negative bacteria (*Escherichia coli*, *Enterococcus aerogenes*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *Shigella dysenteriae* and *Vibrio cholerae*). These bacterial strains were isolated from clinical samples and were obtained from the Microbiology Laboratory, Health Polytechnique, Cimahi, Indonesia. The bacterial isolate to be tested was inoculated onto a Mueller Hinton Agar (MHA) plate and then incubated for 24 hours at 37°C. The bacteria colonies from the fresh agar plate were transferred into a sterile capped glass tube containing a sterile broth or saline solution (NaCl 0.9% b/v) using a sterile loop or cotton swab and mixed well. The suspension was adjusted to achieve a turbidity equivalent to a 0.5 McFarland turbidity standard. This resulted in a suspension containing approximately 1 x 10^8 CFU/mL.

4.1 Determination of Minimum Inhibitory Concentration [37]

The minimum inhibitory concentration (MIC) is defined as the lowest concentration at which no visible bacterial growth is observed. Determination of the MIC was executed using broth microdilution according to the method suggested by the Clinical and Laboratory Standards Institute (CSLI) [37]. The samples were dissolved in dimethyl sulfoxide (DMSO). The samples were prepared to achieve 250 μg/mL in the first well. Two-fold dilution of samples was performed in a 96-wells microplate over a range of 1.95 to 250 μg/mL. This was achieved by filling all wells with 200 µL of Mueller Hinton Broth (MHB) medium. Then 200 µL of sample (500 μg/mL) was transferred into the first well. Two-fold serial dilution was performed by transferring 200 µL of the mixture from the first well into the next consecutive well until the end of the row. At the last well, 200 µL of the mixture was discharged so that the total volume solution in each well was 200 µL. Then 10 µL bacterial suspension was transferred into all wells. The microplate was incubated for 24 hours at 37°C. Bacterial growth was determined using a universal microplate reader. For all samples, positive and negative controls were performed in duplicate. The positive controls used in this assay were chloramphenicol and amoxycillin.

4.2 Determination of Minimum Bactericidal Concentration [37]

The minimum bactericidal concentration (MBC) is defined as the lowest concentration at which colonies fail to grow after being incubated. In order to determine the MBC, an aliquot was removed from the wells that showed no bacterial growth and streaked onto an MHA plate and incubated under the same conditions (24 hours at 37°C).

Acknowledgements

References

[1]   Saleem, M., Nazir, M., Ali, M.S., Hussain, H., Lee, Y.S., Riaza, N. & Jabbar, A., *Antimicrobial Natural Products: An Update on Future Antibiotic Drug Candidates,* Nat. Prod. Rep., **27**, pp. 238-254, 2010.

[2]   Abreu, A.C., McBainb, A.J. & Simoes, M., *Plants as Sources of New Antimicrobials and Resistance-Modifying Agents*, Nat. Prod. Rep., **29**, pp. 1007-1021, 2012.

[3]   Sjamsul, S.A., Hakim, E.H., Makmur, L., Syah, Y.M., Juliawaty, L.D. & Mujahidin, M.*, Chemistry and Uses of Indonesian Plant Drugs*, *Vol. I*, ITB Publisher, pp. 143-152, 2007, (text in Indonesian)

[4]   Rimpler, H., Hansel, R. & Kochendoefer, L., *Xanthorrhizol, a New Sesquiterpene from Curcuma xanthorrhiza*, Z. Naturforsch. B., **25B**, pp. 995-998, 1970.

[5]   Itokawa, H., Hirayama, F., Funakoshi, K. & Takeya, K., *Studies on the Antitumor Bisabolane Sesquiterpenoids Isolated from Curcuma xanthorrhiza,* Chem. Pharm. Bull, **33**, pp. 3488-3492, 1985.

[6]   Yamazaki, M., Maebayashi, Y., Iwase, N. & Kaneko, .T., *Studies on Pharmacologically Active Principles From Indonesian Crude Drugs. II. Hypothermic Principle from Curcuma xanthorrhiza Roxb*, Chem. Pharm. Bull, **36**, pp. 3488-3492, 1988.

[7]   Uehara, S., Yasuda, I., Takeya, K., Itokawa, H. & Iitaka, Y., *New Bisabolane Sesquiterpenoids from the Rhizomes of Curcuma xanthorrhiza (Zingiberaceae),* Chem. Pharm. Bull, 38, 261-263, 1990.

[8]   Uehara, S., Yasuda, I., Takeya, K. & Itokawa, H., *Terpenoids and Curcuminoids of the Rhizoma of Curcuma xanthorrhiza Roxb*, Yakugaku Zasshi, **112**, pp. 817-823, 1992.

[9]   Claeson, P., Panthong, A., Tuchinda, P., Reutrakul, V., Kanjanapothi, D., Taylor, W.C. & Santisuk, T., *Three Non-Phenolic Diarylheptanoids with Anti-Inflammatory Activity from Curcuma xanthorrhiza*, Planta Med., **59**, pp. 451-454, 1993.

[10] Suksamrarn, A., Eiamong, S., Piyachaturawat, P. & Charoenpiboonsin, J., Phenolic diarylheptanoids from *Curcuma xanthorrhiza*, Phytochemistry, 36, 1505-1508, 1994.

[11] Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S.S., Keum, Y.,-S., Park, K.-K. & Lee, S.S., *Molecular Mechanisms Underlying Chemopreventive Activities of Anti-inflammatory Phytochemicals: Down-Regulation of*

COX-2 and iNOS through Suppression of NF-αB Activation, Mutation Res., **480-481**, pp. 243-268, 2001.

[12] Miquel, J., Bernd, A., Sempere, J.M., Díaz-Alperi, J. & Ramírez, A., *The Curcuma Antioxidants: Pharmacological Effects and Prospects for Future Clinical Use. A Review*, Arch. Gerontol. Geriatr., **34**, pp. 37-46, 2002.

[13] Maheshwari, R.K., Singh, A.K., Gaddipati, J. & Srimal R.C., *Multiple Biological Activities of Curcumin: A Short Review*, Life Sci., **78**, pp. 2081-2087, 2006.

[14] Mary Helen, P.A., Susheela, G.K., Jayasree, S., Nizzy, A.M., Rajagopal, B. & Jeeva, S., *Phytochemical Characterization and Antimicrobial Activity of Curcuma xanthorrhiza Roxb.*, Asian Pac. J. Trop. Biomed., S637-S640, 2012.

[15] Rukayadi, Y., Han, S., Yong, D. & Hwang, J.-K., *In Vitro Activity of Xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis Biofilms*, Med. Mycol., **49**, pp. 1-9, 2010.

[16] Rukayadi, Y., Lee, K., Lee, M.-S., Yong, D. & Hwang, J.-K., *Synergistic Anticandidal Activity of Xanthorrhizol in Combination with Ketoconazole or Amphotericin B,* FEMS Yeast Res., **9**, pp. 1302-1311, 2009.

[17] Yanti, Rukayadi, Y., Lee, K., Han, S. & Hwang, J.-K., *Anti-biofilm Activity of Xanthorrhizol Isolated from Curcuma xanthorrhiza Roxb. Against Bacterial Biofilms Formed by Saliva and Artificial Multi-Species Oral Strains*, Food Sci. Biotechnol., **18**, pp. 556-560, 2009.

[18] Lee, Y.L., Shim, J.-S., Rukayadi, Y. & Hwang, J.-K., *Antibacterial Activity of Xanthorrhizol Isolated from Curcuma xanthorrhiza Roxb. against Foodborne Pathogens*, J. Food Protect., **71**, pp. 1926-1930, 2008.

[19] Demain, A.L. & Sanchez, S., *Microbial Drug Discovery: 80 Years of Progress*, J. Antibiotics, **62**, pp. 5-16, 2009.

[20] Yasni, S., Imaizumi, K., Sin, K., Sugano, M., Nonaka, G. & Sidik, *Identification of an Active Principle in Essential Oils and Hexane-Soluble Fractions of Curcuma xanthorrhiza Roxb. Showing Triglyceride-Lowering Action in Rats*, Food Chem. Toxic., **32**, pp. 273-278, 1994.

[21] Devaraj, S., Ismail, S., Ramanathan, S., Marimuthu, S. & Fei, Y.M., *Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb*, J. Med. Plants Res., **4**, pp. 2512-2517, 2010.

[22] Devaraj, S., Esfahani, A.S., Ismail, S., Ramanathan, S. & Yam, M.F., *Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb.*, Molecules, **15**, pp. 2925-2934, 2010.

[23] Sukandar, E.Y., Nurdewi & Elfahmi, *Antihypercholesterolemic Effect of Combination of Guazuma ulmifolia Lamk. Leaves and Curcuma*

xanthorrhiza Roxb. Rhizomes Extract in Wistar Rats, Int. J. Pharm., **8**, pp. 277-282, 2012.

[24] Jae, H.P., Kwang, K.P., Mi, J.K., Jae, K.H., Sun, K.P. & Won, Y.C., *Cancer Chemoprotective Effects of Curcuma xanthorrhiza*, Phytotherapy Res., 22, 695-698, 2008.

[25] Kim, H.S., Choi, C.H., Kwon, H.K. & Kim, B.I., *Combined Inhibitory Effect of Curcuma xanthorrhiza extract and Xylitol on Streptococcus mutons and Actinomyces viscosus*, Key Eng. Mat., **342-343**, pp. 861-864, 2007.

[26] Kim, J.-E., Kim, H.-E., Hwang, J.-K., Lee, H.-J., Kwon, H.-K. & Kim, B.-I., *Antibacterial Characteristics of Curcuma xanthorrhiza Extract on Streptococcus mutons Biofilm*, J. Microbiol., **46**, pp. 228-232, 2008.

[27] Itokawa, H., Hirayama, F., Funakoshi, K., Takeya, K., *Studies on the Antitumor Bisabolane Sesquiterpenoids Isolated from Curcuma xanthorrhiza*, Chem. Pharm. Bull., **33**, pp. 3488-3492, 1985.

[28] Choi, M.-A., Kim, S.H., Chung, W.-Y., Hwang, J.-K. & Park, K.-K., *Xanthorrhizol, a Natural Sesquiterpenoid from Curcuma xanthorrhiza, has an Anti-Metastatic Potential in Experimental Mouse Lung Metastasis Model*, Biochem. Biophys. Res. Commun., **326**, pp. 210-217, 2004.

[29] Ismail, N., Lope Pihie, A.H. & Nallapan, M., *Xanthorrhizol Induces Apoptosis via the Up-regulation of Bax and p53 in HeLa cells*, Anticancer Res., **25**(3B), pp. 2221-2227, 2005.

[30] Cheah, Y.H., Azimahtol, H.L.P. & Abdullah, N.R., *Xanthorrhizol Exhibits Antiproliferative Activity on MCF-7 Breast Cancer Cells via Apoptosis Induction*, Anticancer Res., **26**(6B), pp. 4527-4534, 2006.

[31] Handayani, T., Sakinah, S., Nallappan, M. & Pihie, A.H.L., *Regulation of p53-, Bcl-2- and Caspase-Dependent Signaling Pathway in Xanthorrhizol-Induced Apoptosis of HepG2 Hepatoma Cells*, Anticancer Res., **27**, pp. 965-971, 2007.

[32] Yew, H.C., Nordin, F.J., Thiam, T.T., Azimahtol, H.L.P., Abdullah, N.R. & Ismail, Z., *Antiproliferative Property and Apoptotic Effect of Xanthorrhizol on MDA-MB-231 Breast Cancer Cells*, Anticancer Rese., 28(6 A), pp. 3677-3689, 2008.

[33] Cheah, Y.H., Nordin, F.J., Sarip, R., Tee, T.T., Azimahtol, H.L.P., Sirat, H.M., Rashid, B.A.A., Abdullah, N.R. & Ismail, Z., *Combined Xanthorrhizol-Curcumin Exhibits Synergistic Growth Inhibitory Activity via Apoptosis Induction in Human Breast Cancer Cells MDA-MB-231*, Cancer Cell Internat., **9**, art. no. 1, 2009.

[34] Kang, Y.-J., Park, K.-K., Chung, W.-Y., Hwang, J.-K. & Lee, S.K., *Xanthorrhizol, a Natural Sesquiterpenoid, Induces Apoptosis and Growth Arrest in HCT116 Human Colon Cancer Cells*, J. Pharm. Sci., **111**, pp. 276-284, 2009.

[35] Tee, T.-T., Cheah, Y.-H., Meenakshii, N., Mohd Sharom, M.Y. & Azimahtol Hawariah, L.P., *Xanthorrhizol Induced DNA Fragmentation in HepG2 Cells Involving Bcl-2 Family Proteins*, Biochem. Biophys. Res. Commun., **420**, 834-838, 2012.

[36] Kim, J.Y., An, J.M., Chung, W.-Y., Park, K.-K., Hwang, J.K., Kim, D.S., Seo, S.R. & Seo, J.T., *Xanthorrhizol Induces Apoptosis through ROS-Mediated MAPK Activation in Human Oral Squamous Cell Carcinoma Cells and Inhibits DMBA-Induced Oral Carcinogenesis in Hamsters*, Phytother. Res., **27**, 493-498, 2013.

[37] CSLI, *Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement*, CLSI Document M100-S22, Wayne, PA: Clinical and Laboratory Standards Institute, 2012.